Prelude Capital Management, LLC Cel Sci Corp Call Options Transaction History

Prelude Capital Management, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$7.1 - $12.82 $217,260 - $392,292	-30,600 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$7.64 - $12.49 $233,784 - $382,194	30,600 New	30,600 $336,000
Q1 2020 May 15, 2020	SELL	$7.54 - $17.05 $4,524 - $10,230	-600 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.71 - $9.55 $4,026 - $5,730	600 New	600 $5,000

6.16M

16.6K

148K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $48.6M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.